article
13 December 2019 | By Dr David Murray (AstraZeneca), Dr Mark Wigglesworth (AstraZeneca), Marian Preston (AstraZeneca)
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.